DexCom, Inc. (DXCM)
$84.11-0.36%Close
SELLBEAR · day 10
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV16.9%–98.7%
- Market cap
- $32.5B
- Beta
- 1.48
- P/E (TTM)
- 32.20
- IV-%ile
- 58
- IV ATM
- 43.3%
- Short % float
- 3.65%
- Days to cover
- 3.2
- SI change
- -18.8%
- 1W
- -1.46%
- 1M
- -0.47%
- vs SPY 1W
- -2.62%
- vs SPY 1M
- -3.47%
Industry peers
FMP comparable companies · ranked by market cap
- 603087.SSGan & Lee Pharmaceuticals.$46.3B$77.40
- PODDSELLInsulet Corp.$9.3BRECOVERYQ 16$134.36+0.60%
- YPHDFYpsomed Holding AG$5.7B$436.55
- MMEDSELLMiniMed Group, Inc.$5.4BQ 22$19.11-0.45%
- TNDMSELLTandem Diabetes Care, Inc.$1.1BCRISISQ -8$15.84+2.74%
- BBNXSELLBeta Bionics, Inc.$813MCRISISQ -6$18.08+1.15%
- MMEDVMiniMed Group, Inc.$540M$19.30
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on DXCM?
- LOPJLB’s latest quantitative signal on DexCom, Inc. (DXCM) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is DXCM in?
- DexCom, Inc. (DXCM) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does DexCom, Inc. (DXCM) do?
- DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes…